This study plans to learn more about the effects of a medicine called baricitinib on the
progression of COVID-19 (coronavirus disease of 2019), the medical condition caused by the
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Baricitinib is FDA-approved for
the treatment of rheumatoid arthritis, an autoimmune condition. This study intends to define
the impact of baricitinib on the severity and progression of COVID-19. This drug might to
lower the hyperinflammation caused by the virus, which would prevent damage to the lungs and
possibly other organs.
The study will recruit patients who have been diagnosed with COVID-19.
The goal is to recruit 80 patients.